title: Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.
abstract: The aim of this study is to investigate whether an active immunoprophylactic approach combining specific antigens and adjuvant stimuli would be able to inhibit prostate carcinogenesis in transgenic TRAMP mice. A vaccine consisting of allogeneic large T antigen (TAg)-positive SV40-transformed cells combined with systemic recombinant IL-12 was administered to TRAMP mice, starting from when they were still tumor-free at 5-6 weeks of age. The combined vaccine significantly inhibited prostate carcinogenesis, giving a more than doubled median latency time of prostatic tumors (53 weeks in comparison to 26 weeks in control mice). Vaccination with cells alone or IL-12 treatment alone was poorly effective (median latency of 30 and 39 weeks, respectively). The combined vaccine induced a very high CD4 response biased toward the Th1 pathway, with the induction of a humoral response that included TAg-specific antibodies. Therefore, such active immunoprophylactic approach based on the combination of allogeneic SV40 TAg-positive cells and systemic administration of recombinant IL-12 significantly delayed autochthonous urogenital carcinogenesis driven by SV40 TAg in TRAMP mice.
authors.affiliation: Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy. carla.degiovanni@unibo.it
authors.forename: Carla
authors.initials: C
authors.lastname: De Giovanni
authors.forename: Stefania
authors.initials: S
authors.lastname: Croci
authors.forename: Giordano
authors.initials: G
authors.lastname: Nicoletti
authors.forename: Lorena
authors.initials: L
authors.lastname: Landuzzi
authors.forename: Arianna
authors.initials: A
authors.lastname: Palladini
authors.forename: Tania
authors.initials: T
authors.lastname: Pannellini
authors.forename: Ludovica
authors.initials: L
authors.lastname: Borgia
authors.forename: Manuela
authors.initials: M
authors.lastname: Iezzi
authors.forename: Emma
authors.initials: E
authors.lastname: Di Carlo
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Orengo
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Kennedy
authors.forename: Pier-Luigi
authors.initials: PL
authors.lastname: Lollini
authors.forename: Patrizia
authors.initials: P
authors.lastname: Nanni
authors.forename: Piero
authors.initials: P
authors.lastname: Musiani
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D019496:Cancer Vaccines; D002460:Cell Line; D002471:Cell Transformation, Neoplastic / Q000276:immunology* / Q000473:pathology*; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008854:Microscopy, Electron; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D015996:Survival Rate
chemical_list: D019496:Cancer Vaccines